Global Pharmaceutical Continuous Manufacturing Market Expected to Reach $855 Million by 2026

According to a new report published by Allied Market Research, titled, " Pharmaceutical Continuous Manufacturing Market, by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global pharmaceutical continuous manufacturing market was valued at $393 million in 2018, and is expected to reach $855 million by 2026, growing at a CAGR of 10.2% from 2019 to 2026.   

Continuous manufacturing is an advanced manufacturing approach to provide pharmaceutical products with enhanced quality, improved yield, reduced cost within shorter time period. Pharmaceutical continuous manufacturing market is expected to witness significant grow growth during the forecast period, due to increase in adoption of continuous manufacturing systems over the existing drug manufacturing process, technological advancements, initiatives taken by the Food and drug Administration (FDA) for promoting the use of pharmaceutical continuous manufacturing for modernizing pharmaceutical manufacturing, and advantage over the batch manufacturing. However, higher cost of pharmaceutical continuous manufacturing systems restrain the market growth. 

Depending on product, the market is categorized into integrated continuous systems, semi-continuous systems, and control & software. Presently, the integrated continuous systems dominates the global market, and is anticipated to continue this trend over the forecast period. This is attributed to rise in adoption of integrated continuous manufacturing (ICM) systems, technological advancements, and rise in preference for ICM systems as compared to the existing drug manufacturing systems. 

By application, the global pharmaceutical continuous manufacturing market size is segregated into final drug product manufacturing and API manufacturing. At present, the final drug product manufacturing segment is the major revenue generator, and is anticipated to experience significant growth during the forecast period due to surge in adoption of continuous manufacturing systems in pharmaceutical companies to improve yield, reduced cost of pharmaceutical substances, and to develop drugs within shorter time.

Key Findings of the Pharmaceutical Continuous Manufacturing Market :

• On the basis of product, the integrated continuous systems segment held more than 60% share in the global market in 2018.
• By end user, the pharmaceutical companies segment exhibits fastest growth, and is expected to grow at a CAGR of 10.7% from 2019 to 2026. 
• Depending on application, the final drug product manufacturing segment held largest market share in 2018, and is expected to remain dominant throughout the forecast period. 
• Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 11.5% during the forecast period. 

North America accounted for approximately one-half of the global pharmaceutical continuous manufacturing market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to higher adoption of pharmaceutical continuous manufacturing systems, increase in presence of pharmaceutical companies, availability of well-developed healthcare infrastructure, wide availability of advanced pharmaceutical continuous manufacturing systems, and supportive government policies for adoption of continuous manufacturing systems. However, Asia-Pacific is expected to experience fastest pharmaceutical continuous manufacturing market growth during the forecast period, majorly due to increase in adoption of pharmaceutical continuous manufacturing systems.